デフォルト表紙
市場調査レポート
商品コード
1413901

膠原病血管疾患市場:製品、適応症、最終用途別-2024-2030年の世界予測

Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.33円
膠原病血管疾患市場:製品、適応症、最終用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

膠原病血管疾患市場規模は2023年に298億3,000万米ドルと推計され、2024年には322億1,000万米ドルに達し、CAGR 8.70%で2030年には535億1,000万米ドルに達すると予測されます。

世界の膠原病血管疾患市場

主な市場の統計
基準年[2023] 298億3,000万米ドル
予測年[2024] 322億1,000万米ドル
予測年 [2030] 535億1,000万米ドル
CAGR(%) 8.7%
膠原病血管疾患 Market-IMG1

膠原病血管疾患は、臓器や身体の他の部分を支えるタンパク質を多く含む組織が関与する疾患群です。この結合組織は、皮膚、腱、骨、軟骨、血管の強度、弾力性、構造に不可欠です。膠原病血管疾患は、遺伝性のものや、免疫システムの過剰な働きによって引き起こされるものがあり、その結果、身体が自分自身の組織を攻撃してしまう自己免疫疾患になることがあります。これらの疾患には、罹患した臓器や組織を損傷し機能不全に陥らせる炎症を含む共通の特徴があることが多いです。このカテゴリーには、関節リウマチ、強皮症、全身性エリテマトーデス、多発性筋炎、皮膚筋炎、全身性硬化症など、様々な疾患が含まれます。膠原病血管疾患市場は、結合組織に影響を及ぼす疾患を対象とした診断、治療、治療薬、サービスなどの医療ソリューションの需要と供給を包含します。この市場の用途には、臨床診断、治療、継続的な患者管理が含まれます。エンドユーザーは通常、病院、診療所、リウマチ専門センター、在宅ケア環境などのヘルスケア施設です。この市場はまた、研究機関や学術機関、新しい治療法の開発に携わる製薬会社やバイオテクノロジー企業にもサービスを提供しています。膠原病血管疾患市場のニーズに影響を与える主な要因としては、膠原病血管疾患に対する認識と理解の高まり、世界の自己免疫疾患の罹患率の上昇、ヘルスケアインフラの改善、医療サービスへのアクセシビリティの向上などが挙げられます。しかし、先進的な治療や投薬に伴う高額な費用、政府の厳しい規制や承認プロセスなどの課題に直面しています。一方、膠原病血管疾患に対するニーズは、遺伝子治療や幹細胞治療における進行中の進歩、患者管理のための遠隔医療、モバイルヘルスアプリケーション、ウェアラブルの採用など、いくつかの急成長する機会を提示しています。

地域別洞察

米国は、確立されたヘルスケア・インフラ、患者の意識、自己免疫疾患の罹患率の高さにより、CVDsの重要な市場となっています。技術革新に注力する大手製薬企業の存在と政府の支援政策が市場拡大に寄与しています。南米では、ヘルスケアへのアクセスが改善し、国民の疾患に対する意識が高まるにつれて膠原病血管疾患市場が拡大しています。ヘルスケア提供の強化に向けた政府の取り組みや、医学研究のための国際的な協力関係が、市場をさらに押し上げると予想されます。EUのKEYWORDに対するニーズは、国民皆保険制度が利用可能であることと、研究開発に力を入れていることが特徴です。医薬品の承認に関する厳しい規制が、高水準の医療を保証しています。この地域の消費者は最先端の治療施設を期待し、治療の有効性と安全性プロファイルに後押しされています。中東では膠原病血管疾患を含む自己免疫疾患が増加しており、ヘルスケア部門が発展しているため、国際的なガイドラインや医薬品への依存度が高いです。アフリカでは膠原病血管疾患の管理能力にばらつきがあり、多くの地域でこれらの疾患の有病率が高く、先進的な治療法が不足しています。中国市場は、近代的なヘルスケアシステムへの移行に伴い急速に拡大しており、政府および民間セクターによるヘルスケアへの投資の増加と、世界医薬品へのアクセスの向上が顧客ニーズに影響を及ぼしています。日本市場は、ヘルスケアにおける高度な技術統合を反映しており、消費者層はイノベーションと治療の質に傾斜しています。

FPNVポジショニング・マトリックス

FPNVポジショニング・マトリックスは膠原病血管疾患市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、膠原病血管疾患市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-膠原病血管疾患市場の市場規模および予測は?

2-膠原病血管疾患市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-膠原病血管疾患市場における技術動向と規制の枠組みは?

4-膠原病血管疾患市場における主要ベンダーの市場シェアは?

5-膠原病血管疾患市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 膠原病血管疾患の認識と理解の向上
      • 世界的に自己免疫疾患の発生率が上昇
      • ヘルスケアインフラの改善と医療サービスへのアクセスの向上
    • 抑制要因
      • 先進的な治療や投薬に伴う高額な費用
    • 機会
      • 遺伝子治療と幹細胞治療の継続的な進歩
      • 患者管理のための遠隔医療、モバイル医療アプリケーション、ウェアラブルの採用
    • 課題
      • 厳格な政府規制と承認プロセス
  • 市場セグメンテーション分析
    • 製品:膠原病血管疾患での生検キットの使用の増加
    • 適応症:皮膚筋炎の適応症としての利用拡大
    • 最終用途:さまざまな健康状態を診断するために、診断センターや研究所間での使用を拡大
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 膠原病血管疾患市場:製品別

  • 診断
    • 生検
    • 血液検査
    • 心エコー図
    • 画像検査
    • 尿検査
  • 治療法
    • 理学療法

第7章 膠原病血管疾患市場適応症別

  • 強直性脊椎炎
  • 皮膚筋炎
  • 結節性多発性動脈炎
  • 多発性筋炎
  • 乾癬性関節炎
  • 再発性多発性軟骨炎
  • 関節リウマチ
  • 強皮症
  • 全身性エリテマトーデス
  • 血管炎

第8章 膠原病血管疾患市場:最終用途別

  • 診断センターと研究所
  • 病院とクリニック

第9章 南北アメリカの膠原病血管疾患市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の膠原病血管疾患市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの膠原病血管疾患市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析
    • 契約、コラボレーション、パートナーシップ
    • 新製品発売と機能強化
    • 受賞・表彰・拡大

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Apollo Health and Lifestyle Limited
    • Augurex Life Sciences Corporation
    • Bayer AG
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd
    • Getinge AB
    • Gilead Sciences, Inc.
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • LeMaitre Vascular, Inc.
    • Merck KGaA
    • Novartis AG
    • PerkinElmer, Inc.
    • Pfizer Inc,
    • QIAGEN GmbH
    • Siemens AG
    • Thermo Fisher Scientific, Inc.
    • Trinity Biotech PLC
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
  • FIGURE 7. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 240. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. COLLAGEN VASCULAR DISEASES MARKET LICENSE & PRICING
目次
Product Code: MRR-144C638C8F84

[195 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.

Global Collagen Vascular Diseases Market

KEY MARKET STATISTICS
Base Year [2023] USD 29.83 billion
Estimated Year [2024] USD 32.21 billion
Forecast Year [2030] USD 53.51 billion
CAGR (%) 8.7%
Collagen Vascular Diseases Market - IMG1

Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.

Regional Insights

The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Collagen Vascular Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnosis
      • Biopsy
      • Blood Test
      • Echocardiogram
      • Imaging Tests
      • Urinalysis
    • Treatments
      • Medications
      • Physical Therapy
  • Indication
    • Ankylosing Spondylitis
    • Dermatomyositis
    • Polyarteritis Nodosa
    • Polymyositis
    • Psoriatic Arthritis
    • Relapsing Polychondritis
    • Rheumatoid Arthritis
    • Scleroderma
    • Systemic Lupus Erythematosus
    • Vasculitis
  • End-Use
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Collagen Vascular Diseases Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Collagen Vascular Diseases Market?

3. What are the technology trends and regulatory frameworks in the Collagen Vascular Diseases Market?

4. What is the market share of the leading vendors in the Collagen Vascular Diseases Market?

5. Which modes and strategic moves are suitable for entering the Collagen Vascular Diseases Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Collagen Vascular Diseases Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
      • 5.1.1.2. Rising incidence of autoimmune diseases globally
      • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
      • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
    • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
    • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Collagen Vascular Diseases Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.3.1. Biopsy
    • 6.3.2. Blood Test
    • 6.3.3. Echocardiogram
    • 6.3.4. Imaging Tests
    • 6.3.5. Urinalysis
  • 6.3. Treatments
    • 6.4.1. Medications
    • 6.4.2. Physical Therapy

7. Collagen Vascular Diseases Market, by Indication

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Dermatomyositis
  • 7.4. Polyarteritis Nodosa
  • 7.5. Polymyositis
  • 7.6. Psoriatic Arthritis
  • 7.7. Relapsing Polychondritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Scleroderma
  • 7.10. Systemic Lupus Erythematosus
  • 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Agreement, Collaboration, & Partnership
      • 12.3.1.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
    • 12.3.2. New Product Launch & Enhancement
      • 12.3.2.1. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
    • 12.3.3. Award, Recognition, & Expansion
      • 12.3.3.1. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Apollo Health and Lifestyle Limited
    • 13.1.4. Augurex Life Sciences Corporation
    • 13.1.5. Bayer AG
    • 13.1.6. Beckman Coulter, Inc.
    • 13.1.7. Bio-Rad Laboratories Inc.
    • 13.1.8. Boehringer Ingelheim International GmbH
    • 13.1.9. Bristol-Myers Squibb
    • 13.1.10. Eli Lilly and Company
    • 13.1.11. Exagen Inc.
    • 13.1.12. F. Hoffmann-La Roche Ltd
    • 13.1.13. Getinge AB
    • 13.1.14. Gilead Sciences, Inc.
    • 13.1.15. Illumina, Inc.
    • 13.1.16. Laboratory Corporation of America Holdings
    • 13.1.17. LeMaitre Vascular, Inc.
    • 13.1.18. Merck KGaA
    • 13.1.19. Novartis AG
    • 13.1.20. PerkinElmer, Inc.
    • 13.1.21. Pfizer Inc,
    • 13.1.22. QIAGEN GmbH
    • 13.1.23. Siemens AG
    • 13.1.24. Thermo Fisher Scientific, Inc.
    • 13.1.25. Trinity Biotech PLC
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing